Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Niall Mercer Heney, M.D., Mb.Bch,Bao

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Sanchez A, Wszolek MF, Niemierko A, Clayman RH, Drumm M, Rodríguez D, Feldman AS, Dahl DM, Heney NM, Shipley WU, Zietman AL, Efstathiou JA. Incidence, Clinicopathological Risk Factors, Management and Outcomes of Nonmuscle Invasive Recurrence after Complete Response to Trimodality Therapy for Muscle Invasive Bladder Cancer. J Urol. 2018 02; 199(2):407-415. PMID: 28870862.
    Citations: 1     Fields:    
  2. Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CA, Feng FY, Lovett RD, Balogh AG, Souhami L, Rosenthal SA, Kerlin KJ, Dignam JJ, Pugh SL, Sandler HM. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. N Engl J Med. 2017 02 02; 376(5):417-428. PMID: 28146658.
    Citations: 35     Fields:    Translation:Humans
  3. Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, Michaelson MD, Lee RJ, Saylor PJ, Wszolek MF, Feldman AS, Dahl DM, Zietman AL, Efstathiou JA. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol. 2017 06; 71(6):952-960. PMID: 28081860.
    Citations: 7     Fields:    Translation:Humans
  4. Krasnow RE, Drumm M, Roberts HJ, Niemierko A, Wu CL, Wu S, Zhang J, Heney NM, Wszolek MF, Blute ML, Feldman AS, Lee RJ, Zietman AL, Shipley WU, Efstathiou JA. Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy. Eur Urol. 2017 07; 72(1):54-60. PMID: 28040351.
    Citations: 3     Fields:    Translation:Humans
  5. Mak RH, Hunt D, Efstathiou JA, Heney NM, Jones CU, Lukka HR, Bahary JP, Patel M, Balogh A, Nabid A, Leibenhaut MH, Hamstra DA, Roof KS, Jeffrey Lee R, Gore EM, Sandler HM, Shipley WU. Acute and late urinary toxicity following radiation in men with an intact prostate gland or after a radical prostatectomy: A secondary analysis of RTOG 94-08 and 96-01. Urol Oncol. 2016 10; 34(10):430.e1-7. PMID: 27381895.
    Citations:    Fields:    Translation:HumansPHPublic HealthCTClinical Trials
  6. Mitin T, George A, Zietman AL, Heney NM, Kaufman DS, Uzzo RG, Dreicer R, Wallace HJ, Souhami L, Dobelbower MC, Sandler HM, Shipley WU. Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233. Int J Radiat Oncol Biol Phys. 2016 Jan 01; 94(1):67-74. PMID: 26700703.
    Citations: 4     Fields:    Translation:Humans
  7. Eswara JR, Heney NM, Wu CL, McDougal WS. Long-term outcomes of organ preservation in patients with small cell carcinoma of the bladder. Urol Int. 2015; 94(4):401-5. PMID: 25660255.
    Citations: 1     Fields:    Translation:Humans
  8. Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, Kaufman DS, Heney NM, Zietman AL. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2014 Dec 01; 32(34):3801-9. PMID: 25366678.
    Citations: 37     Fields:    Translation:Humans
  9. Mitin T, Shipley WU, Efstathiou JA, Heney NM, Kaufman DS, Lee RJ, Zietman AL. Trimodality therapy for bladder conservation in treatment of invasive bladder cancer. Curr Urol Rep. 2013 Apr; 14(2):109-15. PMID: 23341373.
    Citations: 2     Fields:    Translation:Humans
  10. Coen JJ, Paly JJ, Niemierko A, Kaufman DS, Heney NM, Spiegel DY, Efstathiou JA, Zietman AL, Shipley WU. Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2013 Jun 01; 86(2):311-6. PMID: 23474117.
    Citations: 5     Fields:    Translation:Humans
  11. Oliva E, Pinheiro NF, Heney NM, Kaufman DS, Shipley WU, Gurski C, Spicer B, Paner GP, Gown AM, Amin MB. Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases. Hum Pathol. 2013 May; 44(5):860-6. PMID: 23199526.
    Citations:    Fields:    Translation:Humans
  12. Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, Kaufman DS, Heney NM, Zietman AL. Long-term outcomes in patients with muscle-invasive bladder cancer after bladder-preserving combined-modality therapy: A pooled analysis of RTOG 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2012 Feb 10; 30(5_suppl):264. PMID: 28143313.
    Citations:    
  13. Eswara JR, Efstathiou JA, Heney NM, Paly J, Kaufman DS, McDougal WS, McGovern F, Shipley WU. Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer. J Urol. 2012 Feb; 187(2):463-8. PMID: 22177159.
    Citations: 9     Fields:    Translation:Humans
  14. Efstathiou JA, Spiegel DY, Shipley WU, Heney NM, Kaufman DS, Niemierko A, Coen JJ, Skowronski RY, Paly JJ, McGovern FJ, Zietman AL. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol. 2012 Apr; 61(4):705-11. PMID: 22101114.
    Citations: 56     Fields:    Translation:Humans
  15. Efstathiou JA, Bae K, Shipley WU, Kaufman DS, Hagan MP, Heney NM, Sandler HM. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol. 2009 Sep 01; 27(25):4055-61. PMID: 19636019.
    Citations: 33     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
  16. Heney NM, Kaufman DS, Shipley WU. Surgery: selective bladder-preserving therapy for muscle-invasive cancer. Nat Rev Clin Oncol. 2009 04; 6(4):193-4. PMID: 19333224.
    Citations: 2     Fields:    Translation:Humans
  17. Wo JY, Shipley WU, Dahl DM, Coen JJ, Heney NM, Kaufman DS, Zietman AL. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary? BJU Int. 2009 Jul; 104(2):179-83. PMID: 19154448.
    Citations: 2     Fields:    Translation:Humans
  18. Kaufman DS, Winter KA, Shipley WU, Heney NM, Wallace HJ, Toonkel LM, Zietman AL, Tanguay S, Sandler HM. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology. 2009 Apr; 73(4):833-7. PMID: 19100600.
    Citations: 35     Fields:    Translation:HumansCTClinical Trials
  19. Mak RH, Zietman AL, Heney NM, Kaufman DS, Shipley WU. Bladder preservation: optimizing radiotherapy and integrated treatment strategies. BJU Int. 2008 Nov; 102(9 Pt B):1345-53. PMID: 19035903.
    Citations: 9     Fields:    Translation:Humans
  20. Efstathiou JA, Zietman AL, Kaufman DS, Heney NM, Coen JJ, Shipley WU. Bladder-sparing approaches to invasive disease. World J Urol. 2006 Nov; 24(5):517-29. PMID: 17082940.
    Citations: 2     Fields:    Translation:Humans
  21. Chakravarti A, Winter K, Wu CL, Kaufman D, Hammond E, Parliament M, Tester W, Hagan M, Grignon D, Heney N, Pollack A, Sandler H, Shipley W. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2005 Jun 01; 62(2):309-17. PMID: 15890569.
    Citations: 26     Fields:    Translation:Humans
  22. Michaelson MD, Shipley WU, Heney NM, Zietman AL, Kaufman DS. Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder. Br J Cancer. 2004 Feb 09; 90(3):578-81. PMID: 14760367.
    Citations: 2     Fields:    Translation:Humans
  23. Heney NM, Young RH. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 39-2003. A 33-year-old woman with gross hematuria. N Engl J Med. 2003 Dec 18; 349(25):2442-7. PMID: 14681511.
    Citations: 1     Fields:    Translation:Humans
  24. Shipley WU, Kaufman DS, Zehr E, Heney NM, Lane SC, Thakral HK, Althausen AF, Zietman AL. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology. 2002 Jul; 60(1):62-7; discussion 67-8. PMID: 12100923.
    Citations: 49     Fields:    Translation:Humans
  25. Zietman AL, Grocela J, Zehr E, Kaufman DS, Young RH, Althausen AF, Heney NM, Shipley WU. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder. Urology. 2001 Sep; 58(3):380-5. PMID: 11549485.
    Citations: 15     Fields:    Translation:Humans
  26. Kaufman DS, Winter KA, Shipley WU, Heney NM, Chetner MP, Souhami L, Zlotecki RA, Sause WT, True LD. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist. 2000; 5(6):471-6. PMID: 11110598.
    Citations: 38     Fields:    Translation:HumansCTClinical Trials
  27. Shipley WU, Kaufman DS, Heney NM, Althausen AF, Zietman AL. An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy. J Urol. 1999 Aug; 162(2):445-50; discussion 450-1. PMID: 10411054.
    Citations: 4     Fields:    Translation:Humans
  28. Zietman AL, Shipley WU, Kaufman DS, Zehr EM, Heney NM, Althausen AF, McGovern FJ. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer. J Urol. 1998 Nov; 160(5):1673-7. PMID: 9783929.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  29. Shipley WU, Winter KA, Kaufman DS, Lee WR, Heney NM, Tester WR, Donnelly BJ, Venner PM, Perez CA, Murray KJ, Doggett RS, True LD. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol. 1998 Nov; 16(11):3576-83. PMID: 9817278.
    Citations: 55     Fields:    Translation:HumansCTClinical Trials
  30. Shipley WU, Kaufman DS, Heney NM, Althausen AF, Zietman AL. An update of selective bladder preservation by combined modality therapy for invasive bladder cancer. Eur Urol. 1998; 33 Suppl 4:32-4. PMID: 9615208.
    Citations: 3     Fields:    Translation:Humans
  31. Shipley WU, Zietman AL, Kaufman DS, Althausen AF, Heney NM. Invasive bladder cancer: treatment strategies using transurethral surgery, chemotherapy and radiation therapy with selection for bladder conservation. Int J Radiat Oncol Biol Phys. 1997 Nov 01; 39(4):937-43. PMID: 9369144.
    Citations: 5     Fields:    Translation:Humans
  32. Kanady KE, Shipley WU, Zietman AL, Kaufman DS, Althausen AF, Heney NM. Treatment strategies using transurethral surgery, chemotherapy, and radiation therapy with selection that safely allows bladder conservation for invasive bladder cancer. Semin Surg Oncol. 1997 Sep-Oct; 13(5):359-64. PMID: 9259092.
    Citations:    Fields:    Translation:Humans
  33. Zietman AL, Shipley WU, Heney NM, Althausen AF. The case for radiotherapy with or without chemotherapy in high-risk superficial and muscle-invading bladder cancer. Semin Urol Oncol. 1997 Aug; 15(3):161-8. PMID: 9394911.
    Citations:    Fields:    Translation:Humans
  34. Morris MM, Dallow KC, Zietman AL, Park J, Althausen A, Heney NM, Shipley WU. Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys. 1997 Jul 01; 38(4):731-6. PMID: 9240639.
    Citations: 15     Fields:    Translation:Humans
  35. Kachnic LA, Kaufman DS, Heney NM, Althausen AF, Griffin PP, Zietman AL, Shipley WU. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol. 1997 Mar; 15(3):1022-9. PMID: 9060542.
    Citations: 28     Fields:    Translation:Humans
  36. Colvett KT, Althausen AF, Bassil B, Heney NM, McGovern FV, Young HH, Kaufman DS, Zietman AL, Shipley WU. Opportunities with combined modality therapy for selective organ preservation in muscle-invasive bladder cancer. J Surg Oncol. 1996 Nov; 63(3):201-8. PMID: 8944067.
    Citations:    Fields:    Translation:Humans
  37. Douglas RM, Kaufman DS, Zietman AL, Althausen AF, Heney NM, Shipley WU. Conservative surgery, patient selection, and chemoradiation as organ-preserving treatment for muscle-invading bladder cancer. Semin Oncol. 1996 Oct; 23(5):614-20. PMID: 8893872.
    Citations: 3     Fields:    Translation:Humans
  38. Kachnic LA, Shipley WU, Griffin PP, Zietman AL, Kaufman DS, Althausen AF, Heney NM. Combined modality treatment with selective bladder conservation for invasive bladder cancer: long-term tolerance in the female patient. Cancer J Sci Am. 1996 Mar-Apr; 2(2):79-84. PMID: 9166504.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  39. Zietman AL, Dallow KC, McManus PA, Heney NM, Shipley WU. Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease. Urology. 1996 Feb; 47(2):236-9. PMID: 8607241.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  40. Kaufman DS, Shipley WU, Griffin PP, Heney NM, Althausen AF, Efird JT. Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med. 1993 Nov 04; 329(19):1377-82. PMID: 8413433.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  41. Shipley WU, Kaufmann DS, Griffin PP, Althausen AF, Heney NM, Prout GR. Radiochemotherapy for invasive carcinoma of the bladder. Recent Results Cancer Res. 1993; 126:207-16. PMID: 8456190.
    Citations:    Fields:    Translation:Humans
  42. Heney NM. Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol Clin North Am. 1992 Aug; 19(3):429-33. PMID: 1636228.
    Citations: 42     Fields:    Translation:Humans
  43. Hug EB, Donnelly SM, Shipley WU, Heney NM, Kaufman DS, Preffer FI, Schwartz SM, Colvin RB, Althausen AF. Deoxyribonucleic acid flow cytometry in invasive bladder carcinoma: a possible predictor for successful bladder preservation following transurethral surgery and chemotherapy-radiotherapy. J Urol. 1992 Jul; 148(1):47-51. PMID: 1613879.
    Citations: 3     Fields:    Translation:Humans
  44. Shipley WU, Kaufman DS, Griffin P, Althausen AF, Heney NM, Prout GR. Radio-chemotherapy for invasive carcinoma of the bladder. Front Radiat Ther Oncol. 1992; 26:142-52. PMID: 1511915.
    Citations: 1     Fields:    Translation:Humans
  45. Dugan TC, Shipley WU, Young RH, Verhey LJ, Althausen AF, Heney NM, McManus PL, Abraham EH. Biopsy after external beam radiation therapy for adenocarcinoma of the prostate: correlation with original histological grade and current prostate specific antigen levels. J Urol. 1991 Nov; 146(5):1313-6. PMID: 1719244.
    Citations: 7     Fields:    Translation:Humans
  46. Fung CY, Shipley WU, Young RH, Griffin PP, Convery KM, Kaufman DS, Althausen AF, Heney NM, Prout GR. Prognostic factors in invasive bladder carcinoma in a prospective trial of preoperative adjuvant chemotherapy and radiotherapy. J Clin Oncol. 1991 Sep; 9(9):1533-42. PMID: 1875217.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  47. Prout GR, Shipley WU, Kaufman DS, Griffin PP, Heney NM. Interval report of a phase I-II study utilizing multiple modalities in the treatment of invasive bladder cancer. A bladder-sparing trial. Urol Clin North Am. 1991 Aug; 18(3):547-54. PMID: 1877119.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  48. Prout GR, Shipley WU, Kaufman DS, Heney NM, Griffin PP, Althausen AF, Bassil B, Nocks BN, Parkhurst EC, Young HH. Preliminary results in invasive bladder cancer with transurethral resection, neoadjuvant chemotherapy and combined pelvic irradiation plus cisplatin chemotherapy. J Urol. 1990 Nov; 144(5):1128-34; discussion 1134-6. PMID: 2122007.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  49. Prout GR, Shipley WU, Kaufman DS, Griffin PP, Heney NM. A progress report on the results of multimodality therapy for muscle-invasive bladder cancer. Semin Urol. 1990 Aug; 8(3):201-4. PMID: 2119050.
    Citations:    Fields:    Translation:Humans
  50. Shipley WU, Kaufman DS, Heney NM. Can chemo-radiotherapy plus transurethral tumor resection make cystectomy unnecessary for invasive bladder cancer? Oncology (Williston Park). 1990 Jul; 4(7):25-32; discussion 32-4, 39. PMID: 2143938.
    Citations: 1     Fields:    Translation:Humans
  51. Shipley WU, Kaufman DS, Heney NM, Griffin PP, Althausen AF, Prout GR. The integration of chemotherapy, radiotherapy and transurethral surgery in bladder-sparing approaches for patients with invasive tumors. Prog Clin Biol Res. 1990; 353:85-94. PMID: 2217430.
    Citations:    Fields:    Translation:Humans
  52. Heney NM, Koontz WW, Barton B, Soloway M, Trump DL, Hazra T, Weinstein RS. Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study. J Urol. 1988 Dec; 140(6):1390-3. PMID: 3143016.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  53. Marks LB, Kaufman SD, Prout GR, Heney NM, Griffin PP, Shipley WU. Invasive bladder carcinoma: preliminary report of selective bladder conservation by transurethral surgery, upfront MCV (methotrexate, cisplatin, and vinblastine) chemotherapy and pelvic irradiation plus cisplatin. Int J Radiat Oncol Biol Phys. 1988 Oct; 15(4):877-83. PMID: 3182328.
    Citations: 1     Fields:    Translation:Humans
  54. Heney NM. Intravesical chemotherapy: how effective is it? Urology. 1988 Mar; 31(3 Suppl):17-9. PMID: 3126591.
    Citations: 1     Fields:    Translation:Humans
  55. Shipley WU, Prout GR, Coachman NM, McManus PL, Healey EA, Althausen AF, Heney NM, Parkhurst EC, Young HH, Shipley JW, et al. Radiation therapy for localized prostate carcinoma: experience at the Massachusetts General Hospital (1973-1981). NCI Monogr. 1988; (7):67-73. PMID: 3173505.
    Citations: 2     Fields:    Translation:Humans
  56. Keating MA, Heney NM, Young HH, Kerr WS, O'Leary MP, Dretler SP. Ureteroscopy: the initial experience. J Urol. 1986 Apr; 135(4):689-93. PMID: 3959187.
    Citations: 6     Fields:    Translation:Humans
  57. Shipley WU, Rose MA, Perrone TL, Mannix CM, Heney NM, Prout GR. Full-dose irradiation for patients with invasive bladder carcinoma: clinical and histological factors prognostic of improved survival. J Urol. 1985 Oct; 134(4):679-83. PMID: 4032570.
    Citations: 16     Fields:    Translation:Humans
  58. Heney NM. First-line chemotherapy of superficial bladder cancer: mitomycin vs thiotepa. Urology. 1985 Oct; 26(4 Suppl):27-9. PMID: 3931325.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  59. Koontz WW, Heney NM, Soloway MS, Kluskens L, Hazra TA, Trump DL, Barton B. Mitomycin for patients who have failed on thiotepa. The National Bladder Cancer Group. Urology. 1985 Oct; 26(4 Suppl):30-1. PMID: 3931326.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  60. Keating MA, Young RH, Carr CP, Nikrui N, Heney NM. Condyloma acuminatum of the bladder and ureter: case report and review of the literature. J Urol. 1985 Mar; 133(3):465-7. PMID: 3973998.
    Citations: 1     Fields:    Translation:Humans
  61. Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD, Hawkins IR. Superficial bladder cancer: progression and recurrence. J Urol. 1983 Dec; 130(6):1083-6. PMID: 6644886.
    Citations: 85     Fields:    Translation:Humans
  62. Heney NM, Proppe K, Prout GR, Griffin PP, Shipley WU. Invasive bladder cancer: tumor configuration, lymphatic invasion and survival. J Urol. 1983 Nov; 130(5):895-7. PMID: 6632095.
    Citations: 11     Fields:    Translation:Humans
  63. Prout GR, Griffin PP, Daly JJ, Heney NM. Carcinoma in situ of the urinary bladder with and without associated vesical neoplasms. Cancer. 1983 Aug 01; 52(3):524-32. PMID: 6861089.
    Citations: 10     Fields:    Translation:Humans
  64. Nocks BN, Heney NM, Daly JJ. Primary adenocarcinoma of urinary bladder. Urology. 1983 Jan; 21(1):26-9. PMID: 6823700.
    Citations: 1     Fields:    Translation:Humans
  65. Heney NM, Nocks BN. The influence of perinephric fat involvement on survival in patients with renal cell carcinoma extending into the inferior vena cava. J Urol. 1982 Jul; 128(1):18-20. PMID: 7109059.
    Citations: 2     Fields:    Translation:Humans
  66. Nocks BN, Heney NM, Daly JJ, Perrone TA, Griffin PP, Prout GR. Transitional cell carcinoma of renal pelvis. Urology. 1982 May; 19(5):472-7. PMID: 7080318.
    Citations: 8     Fields:    Translation:Humans
  67. Heney NM, Nocks BN, Daly JJ, Prout GR, Newall JB, Griffin PP, Perrone TL, Szyfelbein WA. Ta and T1 bladder cancer: location, recurrence and progression. Br J Urol. 1982 Apr; 54(2):152-7. PMID: 7082932.
    Citations: 16     Fields:    Translation:Humans
  68. McDermott DW, Bates RJ, Heney NM, Althausen A. Erectile impotence as complication of direct vision cold knife urethrotomy. Urology. 1981 Nov; 18(5):467-9. PMID: 7314336.
    Citations: 3     Fields:    Translation:Humans
  69. Heney NM, Nocks BN, Daly JJ, Blitzer PH, Parkhurst EC. Prognostic factors in carcinoma of the ureter. J Urol. 1981 May; 125(5):632-6. PMID: 7230332.
    Citations: 10     Fields:    Translation:Humans
  70. Heney NM, Prout GR. Preoperative irradiation as an adjuvant in the surgical management of patients with invasive bladder cancer. Urol Clin North Am. 1980 Oct; 7(3):543-9. PMID: 7456166.
    Citations:    Fields:    Translation:Humans
  71. Crooks KK, Hensle TW, Heney NM, Waltman A, Irwin RJ. Ileal conduit hemorrhage secondary to portal hypertension. Urology. 1978 Dec; 12(6):689-93. PMID: 311099.
    Citations: 3     Fields:    Translation:Humans
  72. Heney NM, Dretler SP, Hensle TW, Kerr WS. Autosuturing device in intestinal urinary conduits. Urology. 1978 Dec; 12(6):650-3. PMID: 741542.
    Citations: 2     Fields:    Translation:Humans
  73. Heney NM, Daly J, Prout GR, Nieh PT, Heaney JA, Trebeck NE. Biopsy of apparently normal urothelium in patients with bladder carcinoma. J Urol. 1978 Nov; 120(5):559-60. PMID: 712898.
    Citations: 7     Fields:    Translation:Humans
  74. Nieh PT, Daly JJ, Heaney JA, Heney NM, Prout GR. The effect of intravesical thio-tepa on normal and tumor urothelium. J Urol. 1978 Jan; 119(1):59-61. PMID: 413937.
    Citations: 5     Fields:    Translation:Humans
  75. Heney NM, Szyfelbein WM, Daly JJ, Prout GR, Bredin HC. Positive urinary cytology in patients without evident tumor. J Urol. 1977 Feb; 117(2):223-4. PMID: 833974.
    Citations: 1     Fields:    Translation:Humans
  76. Heney NM. A new technique to aid catheterization of a traumatized urethral stricture. J Urol. 1975 Nov; 114(5):725-9. PMID: 1185870.
    Citations:    Fields:    Translation:Humans
  77. Heney NM, O'Morchoe PJ, O'Morchoe CC. The renal lymphatic system during obstructed urine flow. J Urol. 1971 Oct; 106(4):455-62. PMID: 5119467.
    Citations: 2     Fields:    Translation:Animals
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Heney's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (208)
Explore
_
Co-Authors (26)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH/NCATS Clinical and Translational Science Award (CTSA) program, grant number UL1TR001102, and through institutional support from Harvard University, Harvard Medical School, Harvard T.H. Chan School of Public Health, Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Massachusetts General Hospital and the Dana Farber Cancer Institute.